[HTML][HTML] Tumor-promoting myeloid cells in the pathogenesis of human oncoviruses: potential targets for immunotherapy
Oncoviruses, known as cancer-causing viruses, are typically involved in cancer progression
by inhibiting tumor suppressor pathways and uncontrolled cell division. Myeloid cells are the …
by inhibiting tumor suppressor pathways and uncontrolled cell division. Myeloid cells are the …
Dextran sulfate inhibits angiogenesis and invasion of gastric cancer by interfering with M2-type macrophages polarization
J Guo, Z Li, Q Ma, M Li, Y Zhao, B Li… - Current Cancer Drug …, 2022 - ingentaconnect.com
Purpose: To explore the effect of dextran sulfate (DS) on the angiogenesis, invasion, and
migration of gastric cancer cells by interfering with the polarization of M2-type macrophages …
migration of gastric cancer cells by interfering with the polarization of M2-type macrophages …
Astragaloside IV antagonizes the malignant progression of breast cancer induced by macrophage M2 polarization through the TGF-β-regulated Akt/Foxo1 pathway
Y Yu, J Hao, L Wang, X Zheng, C Xie, H Liu… - … -Research and Practice, 2023 - Elsevier
Abstract Background Astragaloside IV (AS‑IV) was used for breast cancer (BC) treatment in
China from ancient times; however, the mechanism of the prevention effect of AS-IV on BC …
China from ancient times; however, the mechanism of the prevention effect of AS-IV on BC …
A review of recent advances in peptide-based anticancer therapeutic vaccines and nanovaccines in prostate cancer
Immunotherapy is a critical component of treating various malignancies. So far, there have
been numerous attempts to cure prostate cancer operating diverse types of immunotherapy …
been numerous attempts to cure prostate cancer operating diverse types of immunotherapy …
[HTML][HTML] Microfluidic PLGA microcapsules with PD-L1 aptamers and docetaxel encapsulation for enhancing tumor immunity
R Zhang, L Zhong, X Liu, X Liu, Q Chen, P Wu… - Applied Materials …, 2022 - Elsevier
Immunotherapy has made encouraging progress in the field of cancer treatment. Among
them, the programmed cell death-ligand 1 (PD-L1) antibody-mediated immunotherapy has …
them, the programmed cell death-ligand 1 (PD-L1) antibody-mediated immunotherapy has …
[HTML][HTML] Living cell for drug delivery
Y Wu, Y Liu, T Wang, Q Jiang, F Xu, Z Liu - Engineered Regeneration, 2022 - Elsevier
The living cells have been emerged as useful platforms for drug delivery due to their
advantages of good liquidity, stability, and low immunogenicity. In this review, we …
advantages of good liquidity, stability, and low immunogenicity. In this review, we …
Targeted therapy of tumour microenvironment by gold nanoparticles as a new therapeutic approach
N Mahhengam, K Kazemnezhad… - Journal of Drug …, 2022 - Taylor & Francis
Despite advances in cancer diagnosis and treatment, mortality associated with this
malignant disease is still a major challenge in the health system. The tumour …
malignant disease is still a major challenge in the health system. The tumour …
Distinct T helper cell-mediated antitumor immunity: T helper 2 cells in focus
RCMC Silva, MF Lopes, LH Travassos - Cancer Pathogenesis and …, 2023 - mednexus.org
The adaptive arm of the immune system is crucial for appropriate antitumor immune
responses. It is generally accepted that clusters of differentiation 4+(CD4+) T cells, which …
responses. It is generally accepted that clusters of differentiation 4+(CD4+) T cells, which …
Combination immunotherapy of chlorogenic acid liposomes modified with sialic acid and PD-1 blockers effectively enhances the anti-tumor immune response and …
X Li, S Zhu, P Yin, S Zhang, J Xu, Q Zhang, S Shi… - Drug Delivery, 2021 - Taylor & Francis
Melanoma is one of the most common malignant tumors. The anti-PD-1 antibody is used for
the treatment of metastatic melanoma. Treatment success is only 35–40% and a range of …
the treatment of metastatic melanoma. Treatment success is only 35–40% and a range of …
Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy
C Li, L Wang, Z Li, Z Li, K Zhang, L Cao, Z Wang… - International Journal of …, 2024 - Elsevier
Cancer immunotherapy has shown promise in treating various malignancies. However, the
presence of an immunosuppressive tumor microenvironment (TME) triggered by M2 tumor …
presence of an immunosuppressive tumor microenvironment (TME) triggered by M2 tumor …